Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 11;11(4):942.
doi: 10.3390/jcm11040942.

Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature

Francesco Patti  1 , Clara Grazia Chisari  1 , Simona Toscano  1 , Sebastiano Arena  1 , Chiara Finocchiaro  1 , Vincenzo Cimino  2 , Giuseppe Milone  3
Affiliations
Review

Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature

Francesco Patti et al. J Clin Med. .

Abstract

Multiple sclerosis (MS) is a chronic, inflammatory and immune-mediated disease of the central nervous system (CNS), commonly affecting young adults and potentially associated with life-long disability. About 14 disease-modifying treatments (DMTs) are currently approved for the treatment of MS. However, despite the use of highly effective therapies, some patients exhibit a highly active disease with an aggressive course from onset and a higher risk of long-term disability accrual. In the last few years, several retrospective studies, clinical trials, meta-analyses and systematic reviews have investigated autologous hematopoietic stem cell transplantation (AHSCT) as a possible therapeutic option in order to address this unmet clinical need. These studies demonstrated that AHSCT is a highly efficacious and relatively safe therapeutic option for the treatment of highly active MS. Particularly, over recent years, the amount of evidence has grown, with significant improvements in the development of patient selection criteria, choice of the most suitable transplant technique and clinical experience. In this paper, we present six patients who received AHSCT in our MS center and we systematically reviewed recent evidence about the long-term efficacy and safety of AHSCT and the placement of AHSCT in the rapidly evolving therapeutic armamentarium for MS.

Keywords: hematopoietic stem cell transplantation; multiple sclerosis; treatment.

PubMed Disclaimer

Conflict of interest statement

C.G.C. received a research grant from Sanofi and a grant for congress participation from Almirall, Biogen, Merck Serono, Novartis, Roche, Sanofi and TEVA. S.T. declares no conflict of interest. S.A. declares no conflict of interest. V.C. declares no conflict of interest. C.F. declares no conflict of interest. G.M. declares no conflict of interest. F.P. has received honoraria for speaking activities by Bayer Schering, Biogen, Merck Serono, Novartis and Sanofi Aventis; he also served as an advisory board member the following companies: Bayer Schering, Biogen, Merck Serono and Novartis; he was also funded by Pfizer and FISM for epidemiological studies; he received a grant for congress participation from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Roche, Sanofi Aventis and TEVA. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
PRISMA flow. AHSCT, autologous hematopoietic stem cell transplantation.
Figure 2
Figure 2
AHSCT procedure.
See this image and copyright information in PMC

References

    1. Yamout B.I., Alroughani R. Multiple Sclerosis. Semin. Neurol. 2018;38:212–225. - PubMed
    1. McGinley M.P., Goldschmidt C.H., Rae-Grant A.D. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA. 2021;325:765–779. doi: 10.1001/jama.2020.26858. - DOI - PubMed
    1. Giovannoni G., Lang S., Wolff R., Duffy S., Hyde R., Kinter E., Wakeford C., Sormani M.P., Kleijnen J. A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis. Neurol. Ther. 2020;9:359–374. doi: 10.1007/s40120-020-00212-5. - DOI - PMC - PubMed
    1. Muraro P.A., Martin R., Mancardi G.L., Nicholas R., Sormani M.P., Saccardi R. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat. Rev. Neurol. 2017;13:391–405. doi: 10.1038/nrneurol.2017.81. - DOI - PubMed
    1. Alexander T., Farge D., Badoglio M., Lindsay J.O., Muraro P.A., Snowden J.A. Hematopoietic stem cell therapy for autoimmune diseases–Clinical experience and mechanisms. J. Autoimmun. 2018;92:35–46. doi: 10.1016/j.jaut.2018.06.002. - DOI - PubMed

LinkOut - more resources